Eli Lilly, Novo, AbbVie and Boehringer showcase new obesity drug data at European meeting

The European Association for the Study of Diabetes held its annual meeting in Milan, drawing obesity and metabolic disease experts and providing a platform for drugmakers to present emerging weight‑loss therapies.

Eli Lilly highlighted data from its amylin‑Zepbound combination, noting strong efficacy signals that have drawn investor interest following earlier success with its triple‑acting molecule retatrutide.

Novo presented results showing continued weight loss after patients switched to an oral formulation of its therapy, suggesting a potential advantage in convenience and adherence.

AbbVie and Boehringer Ingelheim also shared early data from in‑licensed assets, offering a glimpse of their next‑generation candidates aimed at improving efficacy, safety or dosing convenience.